Keywords: ACC/AHA Clinical Practice Guidelines; acute coronary syndrome; anticoagulants; anticoagulation agents; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; cardioversion; coronary artery disease; coronary heart disease; dabigatran; edoxaban; focused update; hypertension; idarucizumab; myocardial infarction; obesity; percutaneous coronary intervention; risk factors; rivaroxaban; sleep apnea; stents; stroke; thromboembolism; warfarin.